Pharmacokinetics and tolerability of a single inhaled dose of zanamivir in children
| Autor: | Elizabeth K. Hussey, Jeffrey L. Blumer, Bonnie Rosolowski, Amy W. Peng |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Pharmacology
medicine.medical_specialty Inhalation business.industry viruses virus diseases biochemical phenomena metabolism and nutrition respiratory tract diseases Nebulizer Zanamivir Tolerability Pharmacokinetics Oral administration Internal medicine Anesthesia medicine Viral neuraminidase Pharmacology (medical) Dosing business medicine.drug |
| Zdroj: | Current Therapeutic Research. 61:36-46 |
| ISSN: | 0011-393X |
| DOI: | 10.1016/s0011-393x(00)88495-7 |
| Popis: | Objective The purpose of this study was to examine the pharmacokinetics, safety, and tolerability of zanamivir in children. Background Zanamivir is a potent inhibitor of viral neuraminidase that is effective against both influenza A and B infections. Methods A pediatric study was conducted to examine the pharmacokinetics, safety, and tolerability of zanamivir in children who had signs of respiratory illness. Twenty-four children aged 3 months to 12 years received zanamivir administered as a single, orally inhaled, 10-mg dose either by nebulizer (in patients ® (in patients ≥5 years of age). Serum and urine zanamivir concentrations were analyzed both before dosing and from 0.5 to 8 hours after dosing. Results The rate and extent of absorption of zanamivir were independent of the inhalation formulation or of the patient's age. Median maximum serum concentrations were 47 ng/mL in younger patients (aged ≥3 months to Conclusions Results of the present study suggest that a 10-mg dose of zanamivir is safe and well tolerated when used in children who have signs and symptoms of respiratory illness. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|